We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Markers Identified for Early Onset Prostate Cancer Risk

By LabMedica International staff writers
Posted on 17 Jun 2010
Print article
Single nucleotide polymorphisms (SNPs) associated with prostate cancer risk has been confirmed in younger men with aggressive forms of the disease. A single-nucleotide polymorphism is a DNA sequence variation occurring when a single nucleotide in the genome differs between individuals.

Genetics and traditional screening methods could play a role in predicting the risk of prostate cancer in younger men. Early diagnosis and therefore early treatment is more feasible when the Prostate Screening Antigen (PSA) test is combined with specific gene screening,

In a study, carried out by scientists at the University of Michigan Comprehensive Cancer Center (U-M, Ann Arbor, MI, USA), 14 genetic mutations were looked for in 754 men aged 56 or younger with prostate cancer. The screening results from this group were compared with those from 1,163 prostate cancer patients over the age of 56 and 2,713 men without prostate cancer.

The younger men diagnosed with early onset prostate cancer had a greater frequency of risk alleles that either of the other two groups. In addition, 30% of the younger men had aggressive prostate cancer and 41% of these men had at least one first-degree relative with prostate cancer.

Professor Kathleen Cooney, M.D, the lead scientist in this study, said, "Early onset prostate cancer has a strong genetic component, which we saw in this study. Our next step is to look more widely for novel genetic variants among this group of men."

They will next look at the genome of a larger population of men with early onset prostate cancer to find common mutations that may be linked to the disease. The results of the study were presented in June 2010 at the American Society of Clinical Oncology annual meeting,

Prostate cancer is the most common neoplasm amongst men of all races in the U.S., and around 200,000 new cases occur annually and about 28,000 will die from the disease. In the U.K., the incidence rate is 120.7/100,000 and even higher in most western European countries. The risk of prostate cancer increases with age, consequently early diagnosis and treatment can save lives.

Related Links:

University of Michigan
American Society of Clinical Oncology



Gold Member
Hematology Analyzer
Swelab Lumi
Automated Blood Typing System
IH-500 NEXT
New
Human Insulin CLIA
Human Insulin CLIA Kit
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.